The FDA approves OraSure’s (OSUR +0.4%)
OraQuick Ebola Rapid Antigen Test for the presumptive diagnosis of
Ebola virus disease. The agency reviewed the company’s application under
its De Novo premarket review pathway since there were no predicate
devices.
https://seekingalpha.com/news/3505090-fda-oks-orasure-rapid-ebola-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.